Proposal to de-schedule diclofenac defeated

A proposal to un-schedule certain diclofenac preparations has been rejected by the Advisory Committee on Medicines Scheduling, while a new S3 entry has been created for naproxen.

The dicofenac proposal asked for dermal use preparations containing two percent or less of diclofenac to be exempt from scheduling, It was revealed in the recently released papers from the committee’s March meeting.

All dermal preparations containing 4 per cent or less of diclofenac are currently Schedule 2 medicines, except those containing one percent or less of diclofenac, or for the